Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5521277 | Drug Discovery Today: Technologies | 2016 | 8 Pages |
Abstract
To systematically study the pharmacodynamics of a CNS drug early in the development process, we developed and validated a battery of drug-sensitive CNS tests, which we call NeuroCart. Using this test battery, data-intensive phase 1 studies in healthy subjects can be performed to demonstrate the specific, time- and dose-dependent, neurophysiological and/or neuropsychological effects of a compound, thereby confirming whether the test compound reaches its intended target in the CNS - or does not reach its intended target. We use this test battery to demonstrate that a compound passes the blood-brain barrier.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Geert Jan Groeneveld, Justin Luke Hay, Johannes Marinus Van Gerven,